Acquisition of Neurological Biomarker_AMYLOID BETA

This tender concerns the acquisition of a neurological biomarker, specifically Amyloid Beta. The procurement aims to secure a reliable supply of this crucial diagnostic tool, which plays a significant role in the research and clinical assessment of neurodegenerative diseases, particularly Alzheimer's disease. Amyloid Beta is a key protein fragment implicated in the formation of amyloid plaques in the brain, a hallmark pathology of Alzheimer's. Therefore, the availability of high-quality Amyloid Beta biomarkers is essential for diagnostic laboratories, research institutions, and pharmaceutical companies involved in developing and testing new therapeutic interventions. The specific requirements for the biomarker, such as purity, quantity, and format, will be detailed in the tender documentation. Potential bidders are expected to demonstrate their capacity to supply the biomarker consistently and in compliance with relevant quality standards. This acquisition is vital for advancing the understanding and management of neurological conditions, supporting both diagnostic accuracy and the progress of scientific research in the field of neurology.

This is a supplies contract in the health and medical services, Research and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 885.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.